Q3 EPS Estimates for Cogent Biosciences Decreased by Wedbush

Key Points

• Wedbush has decreased its Q3 2025 earnings per share estimate for Cogent Biosciences from ($0.31) to ($0.42), maintaining a "Neutral" rating with a $10.00 target price.
• The company reported an EPS of ($0.53), surpassing the consensus estimate of ($0.55) by $0.02.
• Recent insider activity includes the purchase of 2,777,777 shares by Director Fairmount Funds Management, increasing their ownership by 44.62%.

Cogent Biosciences, Inc. (NASDAQ:COGT - Free Report) - Wedbush cut their Q3 2025 earnings per share estimates for shares of Cogent Biosciences in a research note issued to investors on Tuesday, August 5th. Wedbush analyst D. Nierengarten now expects that the technology company will post earnings of ($0.42) per share for the quarter, down from their previous forecast of ($0.31). Wedbush currently has a "Neutral" rating and a $10.00 price objective on the stock. The consensus estimate for Cogent Biosciences' current full-year earnings is ($2.42) per share. Wedbush also issued estimates for Cogent Biosciences' Q4 2025 earnings at ($0.47) EPS, FY2026 earnings at ($1.46) EPS, FY2027 earnings at ($1.06) EPS and FY2028 earnings at ($0.46) EPS.

Cogent Biosciences (NASDAQ:COGT - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The technology company reported ($0.53) earnings per share for the quarter, topping the consensus estimate of ($0.55) by $0.02.

COGT has been the topic of a number of other reports. JPMorgan Chase & Co. boosted their target price on Cogent Biosciences from $29.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday. Needham & Company LLC reissued a "hold" rating on shares of Cogent Biosciences in a report on Tuesday, June 17th. Citigroup boosted their price target on Cogent Biosciences from $15.00 to $22.00 and gave the company a "buy" rating in a research note on Friday, July 18th. Jefferies Financial Group boosted their price target on Cogent Biosciences from $23.00 to $28.00 and gave the company a "buy" rating in a research note on Monday, July 7th. Finally, Guggenheim restated a "buy" rating and issued a $17.00 price target on shares of Cogent Biosciences in a research note on Tuesday, July 8th. Three equities research analysts have rated the stock with a hold rating, seven have given a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat.com, Cogent Biosciences has an average rating of "Moderate Buy" and an average price target of $18.70.

Cogent Biosciences Stock Up 0.9%

Shares of NASDAQ COGT traded up $0.10 during midday trading on Thursday, hitting $10.96. 1,331,775 shares of the company's stock were exchanged, compared to its average volume of 2,409,835. The firm has a market capitalization of $1.25 billion, a PE ratio of -6.16 and a beta of 0.36. Cogent Biosciences has a 12 month low of $3.72 and a 12 month high of $12.97. The company's 50 day moving average price is $9.24 and its 200 day moving average price is $7.37.

Institutional Trading of Cogent Biosciences

Several large investors have recently modified their holdings of the stock. ProShare Advisors LLC grew its holdings in shares of Cogent Biosciences by 4.1% during the 2nd quarter. ProShare Advisors LLC now owns 26,021 shares of the technology company's stock worth $187,000 after purchasing an additional 1,020 shares in the last quarter. Corton Capital Inc. grew its holdings in shares of Cogent Biosciences by 6.4% during the 2nd quarter. Corton Capital Inc. now owns 17,438 shares of the technology company's stock worth $125,000 after purchasing an additional 1,046 shares in the last quarter. Balyasny Asset Management L.P. lifted its position in shares of Cogent Biosciences by 8.8% during the 4th quarter. Balyasny Asset Management L.P. now owns 20,805 shares of the technology company's stock worth $162,000 after buying an additional 1,687 shares during the last quarter. 49 Wealth Management LLC lifted its position in shares of Cogent Biosciences by 19.0% during the 2nd quarter. 49 Wealth Management LLC now owns 15,508 shares of the technology company's stock worth $111,000 after buying an additional 2,476 shares during the last quarter. Finally, Arizona State Retirement System lifted its position in shares of Cogent Biosciences by 18.0% during the 1st quarter. Arizona State Retirement System now owns 20,567 shares of the technology company's stock worth $123,000 after buying an additional 3,142 shares during the last quarter.

Insider Activity

In related news, Director Fairmount Funds Management Llc bought 2,777,777 shares of Cogent Biosciences stock in a transaction dated Thursday, July 10th. The shares were bought at an average cost of $9.00 per share, with a total value of $24,999,993.00. Following the acquisition, the director owned 9,003,418 shares in the company, valued at $81,030,762. This trade represents a 44.62% increase in their position. The transaction was disclosed in a document filed with the SEC, which is available through this link. Company insiders own 7.29% of the company's stock.

About Cogent Biosciences

Cogent Biosciences, Inc, a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors.